Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05283980 · ClinicalTrials.gov registry record · Phase 2
Pectoral Nerve Blocks (PECs) for Cardiovascular Implantable Electronic Device Placement
A Phase 2 study of Pain and Pain, Postoperative, sponsored by Beth Israel Deaconess Medical Center.
- Active
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
- 1
- Study location
NCT05283980 is a Phase 2 study of Pain and Pain, Postoperative that is active but no longer recruiting, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 62 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05283980, a Phase 2 study of Pain and Pain, Postoperative, is active but no longer recruiting, sponsored by Beth Israel Deaconess Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether administration of a pectoral nerve blocks (Pecs I and II) with 0.25% bupivacaine are more effective as compared to placebo to provide analgesia for cardiac implantable electronic device (CIED) placement in cardiac electrophysiology lab
Conditions Studied
Interventions
- DRUG 0.25% Bupivacaine
Study Locations (1)
Massachusetts
- BIDMC - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2022-11-17 |
| Est. Completion | 2025-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05283980
The ClinicalTrials.gov registry entry for NCT05283980 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 304-participant average among 374 other Pain trials with a reported enrollment target (80% lower). The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Pain appearing as the primary indexed condition, and to 1 intervention - of which 0.25% Bupivacaine is the first listed.
NCT05283980 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05283980 about?
NCT05283980 is a clinical study titled "Pectoral Nerve Blocks (PECs) for Cardiovascular Implantable Electronic Device Placement". The purpose of this study is to determine whether administration of a pectoral nerve blocks (Pecs I and II) with 0.25% bupivacaine are more effective as compared to placebo to provide analgesia for cardiac implantable electronic device (CIED) placement in cardiac electrophysiology lab
What is the current status of trial NCT05283980?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2022-11-17. Estimated completion is 2025-03.
What conditions does trial NCT05283980 study?
This clinical trial studies the following conditions: Pain, Pain, Postoperative, Pain, Acute, Opioid Use, Unspecified, Satisfaction, Patient.
What interventions are being tested in trial NCT05283980?
The interventions under investigation include: 0.25% Bupivacaine (DRUG).
Who is sponsoring clinical trial NCT05283980?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05283980 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism
RECRUITING · Phase 2
-
Cannabidiol and Older Adult Cannabis Users
RECRUITING · Phase 2
-
Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype
RECRUITING · Phase 2
-
Neural Correlates of Hypoalgesia Driven by Observation
RECRUITING · Phase 2
-
Cannabis for Palliative Care in Cancer
RECRUITING · Phase 2
-
Pain After Buffered Vs Non Buffered Articaine
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.